SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia shares are under pressure as traders react to the boards investigation into Jensen Huangs admitted affair with a businesswoman reported to have suspected ties to Chinese intelligence, raising concerns about governance, possible information leaks, and Huangs future as CEO. The community is divided between seeing the probe and leadership uncertainty as a serious overhang and treating the controversy as unrelated to Nvidias AI-chip business and a buying opportunity.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is under heavy selling pressure ahead of its Q3 earnings report, with traders speculating about a possible leak while others see the decline as pre-report positioning; a leak is unconfirmed. Bulls point to growth and potential upbeat guidance, while bears worry that the Eli Lilly obesity-drug deal could pressure margins and profitability.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics quarterly revenue beat and higher full-year outlook, driven by BRIUMVI growth, are the main focus; shares saw a sharp post-results dip and recovery, prompting debate over a sell the news reaction versus short-driven volatility. Traders are also watching for Phase 3 results on subcutaneous BRIUMVI as a next potential catalyst.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWMs sharp rally is drawing attention as small caps outperform, with traders describing a possible low-volume short squeeze and rotation into the Russell 2000. Bulls are chasing calls and citing hopes for easing inflation, while skeptics question the moves strength given reported weak flows and limited volume.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors pending FDA decision on deramiocel for Duchenne muscular dystrophy, focused on the amended upper-limb-function evidence from HOPE-3, is driving attention ahead of the Nov. 22 PDUFA date. Bulls cite the trial data and a letter urging approval from 28 investigators, while skeptics point to FDA scrutiny and the earlier negative advisory-panel vote on the cardiac indication; short-squeeze speculation adds to the debate.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs rally is drawing attention after Oppenheimer upgraded the stock, while Google Clouds use of EPYC processors in its AI infrastructure added a company-specific catalyst. Traders also point to money rotating from Nvidia amid a CEO-related investigation, though some see the move as sentiment-driven and question AMDs valuation.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels SITC findings on immune activation and viral clearance, alongside its positive Phase 3 prostate-cancer results, are drawing attention as the company prepares a BLA for CAN-2409. Bulls see the data as supportive of the regulatory package, while skeptics question filing and manufacturing execution and warn of a possible sell-the-news reaction.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

A quarterly earnings shortfall and reduced full-year revenue guidance, tied largely to federal Dedrone drone deployments being delayed, have driven a sharp selloff. Traders debate whether the decline overreacts to a timing issue or reflects high valuation and weaker near-term growth, with some buying the dip and others expecting further downside.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk shares are rallying sharply ahead of its Q3 earnings report, with traders speculating about short covering and an earnings leak, though neither explanation is confirmed. The move has fueled hopes for a turnaround, while many investors worry that weak results or guidance could erase the gains.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Agility Robotics Inc.

Agility Robotics Inc. - Ordinary Shares - Class A

Post-merger selling in Agility Robotics is drawing attention, with traders pointing to typical de-SPAC volatility and questioning the companys steep losses, limited revenue, and path to commercial scale. Some remain bullish on humanoid robotics and the companys reported orders, but the discussion is dominated by skepticism about valuation and near-term execution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Beats Revenue Estimates

Janux Therapeutics (JANX) delivered earnings and revenue surprises of +24.44% and +34.12%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

AbCellera to Present at the UBS Global Biopharma Conference on November 17, 2026

AbCellera (Nasdaq: ABCL) announced that the Company will present at the UBS Global Biopharma Conference on November 17, 2026. A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the...

Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates

Vir Biotechnology (VIR) delivered earnings and revenue surprises of +28.75% and -132.25%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates

Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of +45.46% and +3.06%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

AbCellera to Present at Upcoming Investor Conferences in November 2026

AbCellera (Nasdaq: ABCL) announced that the Company will present at the following investor conferences: Stifel Healthcare Conference, November 11, 2026 Jefferies Global Healthcare Conference in London, November 16, 2026 A live audio webcast of the presentation may be accessed through a link that...

Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates

Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of +944.64% and +383.11%, respectively, for the quarter ended August 2026. Do the numbers hold clues to what lies ahead for the stock?

AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting

AbCellera (Nasdaq: ABCL) today announced an upcoming poster presentation of Phase 1/2 data on ABCL635 at The Menopause Societys (TMS) 2026 Annual Meeting, to be held October 20 to 24 at the Hilton Bayfront in San Diego, California. Details on AbCelleras poster presentation at TMS are as follows...

AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026

AbCellera (Nasdaq: ABCL) will announce its third quarter 2026 financial results on Monday, November 9, 2026, and hold an earnings conference call at 3:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will...

AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment

AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment AI Drug Discovery Forecasts Vary Widely as Sector Shifts to DeploymentPR NewswireAUSTIN, Texas, Oct. 1, 2026Equity Insider News CommentaryAUSTIN, Texas, Oct. 1, 2026 /PRNewswire/ --Towards Healthcare projects that the global AI...

Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today? 

Equity

The rallies were driven by expanding opportunities tied to biotechnology and artificial intelligence. 


AbCellera Biologics Inc

ABCL  Earnings Call

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

Neutral Sentiment

<ul class="summary-bullets"><li>Iovance shares hit a two-year high of $15.30 after the company raised its 2026 revenue forecast to $410 million-$420 million.</li><li>JPMorgan initiated coverage of AbCellera with an Overweight rating and $17 price target, citing promising ABCL635 data.&nbsp;</li><li>CrowdStrike shares hit a record $267.69 after the company announced plans to bring its Falcon platform to the OpenAI Marketplace.</li></ul>Iovance Biotherapeutics (<a class="mention" data-mention="$IOVA" data-symbol-id="IOVA" href="https://stocktwits.com/symbol/IOVA" target="_blank">IOVA</a>), AbCellera Biologics (ABCL) and CrowdStrike Holdings (CRWD) hit fresh 52-week highs on Tuesday as investors responded to stronger business outlooks, analyst support and AI-driven cybersecurity expansion.&nbsp;Iovance’s stock jumped 31%, while AbCellera and CrowdStrike stocks gained over 6% and 1%, respectively.&nbsp;<h2 class="st-heading-2">Iovance Biotherapeutics Raises Outlook</h2><a href="https://stocktwits.com/symbol/IOVA">Iovance stock</a> reached a two-year high of $15.30 after the biotech company raised its 2026 revenue outlook. The company now sees full-year sales between $410 million and $420 million, representing growth of almost 60% from last year and coming in well ahead of the consensus estimate of $407 million, according to Fiscal.ai data.The improved outlook reflects stronger commercial demand for Amtagvi, the company's tumor-infiltrating lymphocyte therapy for metastatic melanoma. The stronger business outlook also prompted H.C. Wainwright analyst Joseph Pantginis to lift his price target to $20 from $9 while keeping a ‘Buy’ rating.On Stocktwits, retail sentiment around the stock improved to ‘extremely bullish’ from ‘bullish’ territory the previous day.&nbsp;<h2 class="st-heading-2">AbCellera Gains JPMorgan Backing</h2><a href="https://stocktwits.com/symbol/ABCL">AbCellera stock</a> jumped to a four-year high of $15 as JPMorgan began covering the biotechnology company with an ‘Overweight’ rating and a $17 price target, describing the business as approaching a "major value inflection point."The firm pointed to clinical results from ABCL635, AbCellera's internal program targeting NK3R protein to address menopausal hot flashes. JPMorgan highlighted the candidate's combination of efficacy, safety, and dosing convenience.&nbsp;The firm also cited AbCellera's broad collection of pharmaceutical partnerships as support for its technology platform and noted that those relationships can help offset the company's operating expenses. Retail sentiment around the stock improved to ‘extremely bullish’ from ‘bullish’ territory the previous day.&nbsp;<h2 class="st-heading-2">CrowdStrike Expands Into OpenAI Marketplace</h2><a href="https://stocktwits.com/symbol/CRWD">CrowdStrike stock</a> climbed to a record high of $267.69 after the cybersecurity company announced plans to bring its Falcon platform to the OpenAI Marketplace.The move connects CrowdStrike's cloud-based security and threat intelligence capabilities with OpenAI's enterprise AI ecosystem. The integration will give business customers greater security while helping automate responses to potential threats. Investors expect the growing use of AI agents to increase demand for security tools.&nbsp;However, retail sentiment around the stock remained in ‘bearish’ territory.&nbsp;So far this year, <a class="mention" data-mention="$IOVA" data-symbol-id="IOVA" href="https://stocktwits.com/symbol/IOVA" target="_blank">IOVA</a>, ABCL and CRWD stocks have gained between 124% and 429%.Also see:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rum-stock-ticks-higher-overnight-analyst-sees-upside-as-13-billion-anthropic-deal-sets-off-ai-pivot/cZMnABwRBWV">RUM Stock Ticks Higher Overnight: Analyst Sees 94% Upside As $13B Anthropic Deal Sets Off AI Pivot</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the IOVANCE BIOTHERAPEUTICS logo is displayed on the screen of a tablet computer. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Iovance Biotherapeutics (IOVA), AbCellera Biologics (ABCL) and CrowdStrike Holdings (CRWD) hit fresh 52-week highs on Tuesday as investors responded to stronger business outlooks, analyst support and AI-driven cybersecurity expansion.

Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today?

Crowdstrike Holdings Inc

iShares Genomics Immunology and Healthcare ETF

iShares Expanded Tech-Software Sector ETF

Iovance Biotherapeutics Inc

Buying the dip

Selling or trimming

Holding

Waiting for the investigation results to decide

Nvidia ($NVDA) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Stocktwits

) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Current Price	$12.68
Prev Close	$11.88
Open	$11.97
Dividend Yield	0.00%
50-Day Moving Average	$12.28
Beta	1.74
Avg. Volume	4.52M
PE Ratio	-21.81

52-Week High	$15.02
52-Week Low	$2.75
Market Capitalization	$3.85B
EPS (Annual)	-$0.4901
Price to Book	4.06
Revenue Per Employee	$133,679.71

Feed

News

Sentiment

Earnings

Fundamentals

Info

ABCL Fundamentals